CONTROLLED SUBSTANCES ACT

Bills and resolutions

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (see S. 2244), S5062 [24JY] (see H.R. 4131), H7481 [30JY]

——— authorize debarment of certain controlled substances registrants (see H.R. 4806), H8455 [23OC]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (see H.R. 4563), H8080 [27SE]

——— clarify how controlled substance analogues that are imported or offered for import are to be regulated (see S. 2764), S6333 [31OC] (see H.R. 4963), H8718 [31OC]

——— clarify process for registrants to exercise due diligence upon discovering a suspicious order (see H.R. 3878), H7239 [23JY]

——— deem drugs or other substances that act as mu opioid receptor agonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 2580), H3500 [8MY]

——— eliminate separate registration requirement for dispensing narcotic drugs categorized in schedules with lower potential for abuse that are intended for maintenance or detoxification treatment (see S. 2074), S4773 [10JY] (see H.R. 2482), H3439 [2MY]

——— extend temporary scheduling order listing fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5233), H9168 [21NO]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see S. 1622), S3059 [22MY] (see S. 2701), S6155 [24OC] (see S. 3148), S7208 [19DE] (see H.R. 2935), H4119 [22MY] (see H.R. 5421), H10257 [12DE]

——— provide for modification, transfer, and termination of a registration to manufacture, distribute, or dispense controlled substances or list I chemicals (see H.R. 4812), H8455 [23OC]

——— regulate selective androgen receptor modulators in the same manner as anabolic steroids (see S. 2895), S6669 [19NO]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 3070), S7113 [17DE]

——— require health care professionals to certify they will not prescribe more than a seven-day supply of opioids as treatment for acute pain or provide refills as part of their registration to prescribe opioids (see S. 724), S1734 [7MR] (see H.R. 1614), H2583 [7MR]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 424), S1133 [7FE]

Dept. of Justice: make procurement quotas for opioid analgesics publicly available to disclose applications requesting active ingredients and amount of opioids alloted to be produced by manufacturers (see S. 1366), S2742 [8MY] (see H.R. 2582), H3500 [8MY]

——— prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (see H.R. 493), H517 [11JA]

——— require registration of tableting or encapsulating machines to assist law enforcement in identifying counterfeit pill makers (see S. 989), S2189 [2AP] (see H.R. 2020), H2985 [2AP]

Drugs: allow State and tribal regulation of marijuana, maintain application of certain criminal offenses relative to marijuana, prohibit its sale to individuals under 21, and study effects of legalization (see S. 1028), S2269 [4AP] (see H.R. 2093), H3099 [4AP] (see H.R. 3754), H5824 [15JY]

——— decriminalize, expunge prior convictions, tax products to create programs for those adversely affected by War on Drugs, and provide assistance and collect data on small businesses relative to marijuana (see S. 2227), S5012 [23JY] (see H.R. 3884), H7240 [23JY]

——— decriminalize marijuana, use tax revenues to assist certain small businesses, research effects on driving and health, restrict advertising to protect children, and expunge certain marijuana-related convictions (see S. 1552), S2962 [20MY] (see H.R. 2843), H4009 [20MY]

——— decriminalize marijuana at the Federal level and leave States the power to regulate marijuana similar to the power to regulate alcohol (see H.R. 420), H358 [9JA]

——— develop national cannabis research agenda, collect data on cannabis use and impacts on health outcomes, change controlled substance classification of cannabis, and streamline DEA approval of research (see S. 2400), S5248 [31JY] (see H.R. 4322), H7705 [12SE]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans (see H.R. 127), H205 [3JA]

——— focus limited Federal resources on the most serious offenders by modifying sentencing guidelines for certain drug offenses (see S. 2850), S6567 [13NO]

——— improve medical research on marijuana by simplifying registration process to conduct research, facilitating access for such research, and allowing private manufacture and distribution for research purposes (see H.R. 3797), H5998 [17JY]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 601), H674 [16JA]

——— limit application of Federal laws to distribution and consumption of marijuana (see H.R. 1588), H2581 [7MR]

——— make marijuana legal at the Federal level, incentivize States to change marijuana laws that disproportionately impact minority communities, and allow retroactive review of marijuana sentences (see S. 597), S1593 [28FE]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (see H.R. 1456), H2313 [28FE]

——— prohibit knowing possession of a pill press mold with intent to manufacture a counterfeit substance in schedule I or II in a capsule, tablet, and other form intended for distribution (see S. 2573), S5748 [26SE] (see H.R. 4510), H8053 [26SE]

——— provide for legitimate use of medicinal marijuana in accordance with State laws (see H.R. 171), H207 [3JA]

——— provide for taxation and regulation of marijuana products (see S. 420), S1133 [7FE] (see H.R. 1120), H1491 [8FE]

——— provide that Federal law shall not preempt State law in enforcement of Controlled Substances Act criminal penalties for marijuana (see H.R. 2012), H2938 [1AP]

——— reduce gap between Federal and State marijuana policy (see S. 421), S1133 [7FE] (see H.R. 1119), H1491 [8FE]

——— require use of prescription drug monitoring programs and facilitate information sharing among States that receive Federal funding to combat opioid abuse (see S. 516), S1383 [14FE] (see H.R. 3974), H7463 [25JY]

——— reschedule marijuana under the Controlled Substances Act (see H.R. 4323), H7705 [12SE]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (see S. 2032), S4628 [27JN]

FDA: require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 1449), S2815 [14MY] (see H.R. 2732), H3789 [14MY]

Health care professionals: require certain practitioners authorized to prescribe controlled substances to complete continuing education (see S. 1448), S2815 [14MY] (see H.R. 2734), H3789 [14MY]

——— require prescribers of controlled substances to complete training on treating patients with opioid and other substance use disorders and incorporate such training in medical school curricula (see H.R. 4974), H8724 [1NO]

Remarks in House

DEA: eliminate separate registration requirement for dispensing narcotic drugs categorized in schedules with lower potential for abuse that are intended for maintenance or detoxification treatment (H.R. 2482), H3508 [9MY], H7998 [26SE]

Dept. of HHS: research on certain Schedule I drugs that have shown promise in treating critical diseases funding, H4612, H4613 [12JN]

Dept. of Justice: prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (H.R. 493), E36 [11JA]

——— prohibit funding to interfere in marijuana policy of States, District of Columbia, and U.S. territories, H4890, H4891 [19JN]

Drugs: clarify how synthetic drugs known as analogues are to be regulated, H2618 [11MR]

——— decriminalize, expunge prior convictions, tax products to create programs for those adversely affected by War on Drugs, and provide assistance and collect data on small businesses relative to marijuana (H.R. 3884), H7969, H7971 [25SE]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, enable medicinal research, and allow prescription to veterans (H.R. 127), E7 [3JA]

——— prohibit Federal prosecution of residents who are acting in accordance with their State’s marijuana laws (H.R. 1456), H7969, H7971 [25SE]

——— reschedule marijuana under the Controlled Substances Act, H7965, H7969, H7970 [25SE]

Right To Try Act: implementation, H9126 [21NO]

Remarks in Senate

DEA: allow community addiction treatment facilities and community mental health facilities to register to dispense controlled substances through telemedicine (S. 2244), S6280 [30OC]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (S. 2701), S6276 [30OC]

——— include fentanyl-related substances under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (S. 3148), S7236 [19DE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 3070), S7116 [17DE]

Drugs: include all controlled substance analogues under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use, regardless if intended for human consumption, S6279 [30OC]

——— streamline, coordinate and expand research and foster increased communication between doctors and patients relative to cannabidiol and other marijuana components and their medical benefits (S. 2032), S4633 [27JN]

Texts of

S. 1552, Marijuana Freedom and Opportunity Act, S2971 [20MY]

S. 2400, Expanding Cannabis Research and Information Act, S5253 [31JY]

S. 3148, Stopping Overdoses of Fentanyl Analogues Act, S7212 [19DE]